Literature DB >> 15793154

Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2.

Raymund R Razonable1, Martin Henault, Linda N Lee, Carmen Laethem, Paul A Johnston, Harold L Watson, Carlos V Paya.   

Abstract

Amphotericin B (AmB) is a ligand of toll-like receptor 2 (TLR2). Here, we demonstrate the participation of TLR1 in AmB-induced cell activation that led to the secretion of tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-8. Hence, TLR2-TLR1 coactivation serves as the underlying mechanism for the proinflammatory toxicities associated with AmB.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793154      PMCID： PMC1068636          DOI： 10.1128/AAC.49.4.1617-1621.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels.

Authors:  M Arning; K O Kliche; A H Heer-Sonderhoff; A Wehmeier
Journal:  Mycoses       Date:  1995 Nov-Dec       Impact factor: 4.377

2.  Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line.

Authors:  P Legrand; A Vertut-Doi; J Bolard
Journal:  J Antimicrob Chemother       Date:  1996-03       Impact factor: 5.790

Review 3.  Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis.

Authors:  I W Blau; A A Fauser
Journal:  Mycoses       Date:  2000-10       Impact factor: 4.377

4.  A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.

Authors:  H G Prentice; I M Hann; R Herbrecht; M Aoun; S Kvaloy; D Catovsky; C R Pinkerton; S A Schey; F Jacobs; A Oakhill; R F Stevens; P J Darbyshire; B E Gibson
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

Review 5.  Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?

Authors:  J Mehta
Journal:  Leuk Res       Date:  1997-03       Impact factor: 3.156

6.  The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism.

Authors:  Keya Sau; Salamatu S Mambula; Eicke Latz; Philipp Henneke; Douglas T Golenbock; Stuart M Levitz
Journal:  J Biol Chem       Date:  2003-07-14       Impact factor: 5.157

7.  Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells.

Authors:  J D Cleary; S W Chapman; R L Nolan
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity.

Authors:  W R Perkins; S R Minchey; L T Boni; C E Swenson; M C Popescu; R F Pasternack; A S Janoff
Journal:  Biochim Biophys Acta       Date:  1992-06-30

9.  Amphotericin B activation of human genes encoding for cytokines.

Authors:  P D Rogers; J K Jenkins; S W Chapman; K Ndebele; B A Chapman; J D Cleary
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

10.  Streptomyces nodosus sp. n., the amphotericin-producing organism.

Authors:  W H TREJO; R E BENNETT
Journal:  J Bacteriol       Date:  1963-02       Impact factor: 3.490
View more
  21 in total

Review 1.  Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses.

Authors:  N Singh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267

2.  Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study.

Authors:  Renee Donahue Carlson; Melissa A Rolfes; Kate E Birkenkamp; Noeline Nakasujja; Radha Rajasingham; David B Meya; David R Boulware
Journal:  Metab Brain Dis       Date:  2014-01-09       Impact factor: 3.584

3.  Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.

Authors:  Samusi A Adediran; Timothy P Day; Diptesh Sil; Matthew R Kimbrell; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

4.  Toll-Like Receptor 2 and Lipoprotein-Like Lipoproteins Enhance Staphylococcus aureus Invasion in Epithelial Cells.

Authors:  Minh-Thu Nguyen; Loulou Peisl; Francesca Barletta; Arif Luqman; Friedrich Götz
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

5.  Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity.

Authors:  Alicia Ponte-Sucre; Radim Vicik; Martina Schultheis; Tanja Schirmeister; Heidrun Moll
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism.

Authors:  Raymund R Razonable; Martin Henault; Harold L Watson; Carlos V Paya
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.

Authors:  Russell E Lewis; Georgios Chamilos; Randall A Prince; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

Review 8.  Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects.

Authors:  B Eleazar Cohen
Journal:  J Membr Biol       Date:  2010-11-18       Impact factor: 1.843

9.  R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins.

Authors:  Robert A Brown; Jonathon H Gralewski; Albert J Eid; Bettina M Knoll; Robert W Finberg; Raymund R Razonable
Journal:  Transplantation       Date:  2010-04-15       Impact factor: 4.939

10.  The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus.

Authors:  Robert A Brown; Jonathon H Gralewski; Raymund R Razonable
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.